 |
|
Gene therapy increases survival for end-stage head and neck cancer
May 29, 2008HOUSTON - A gene therapy invented at The University of Texas M. D. Anderson Cancer Center is the first to succeed in a U.S. phase III clinical trial for cancer, as announced today at the American Society of Gene Therapy annual meeting in Boston.
Introgen Therapeutics, Inc., reported results of its phase III trial of Advexin(r), a modified adenovirus that expresses the tumor-suppressing gene p53, for end-stage head and neck cancer.
"Cells become cancerous because p53 no longer functions. Restoring p53 works unlike any current cancer treatment because it treats the cancer genome," said Jack Roth, M.D., professor in M. D. Anderson's Department of Thoracic & Cardiovascular Surgery, who invented the drug and co-founded Introgen. He remains a shareholder and paid consultant to Introgen, and the University of Texas System is also a shareholder in Introgen.
The p53 gene is inactivated in many types of cancer. Its normal role is to halt the division of a defective cell and then force the cell to kill itself.
The trial showed that p53 expression in the patient's tumor before treatment is a reliable biomarker for how to treat head and neck cancer. Patients with a favorable p53 profile who received Advexin(r) had a median survival of 7.2 months, compared with 2.7 months for those whose tumor expressed high levels of mutant p53 before treatment. Patients with this unfavorable profile were better off taking the chemotherapy drug methotrexate, resulting in median survival of 5.9 months.
"The important finding is that patients who benefit from treatment can be identified with the p53 biomarker. The biomarker will enable physicians to personalize treatment," said Roth, who also directs M. D. Anderson's W.M. Keck Center for Innovative Cancer Therapies.
Detailed results of the 123-patient clinical trial, led by John Nemunaitis, M.D., executive director of the Mary Crowley Medical Research Center at Baylor-Charles A. Sammons Cancer Center in Dallas, are available at www.introgen.com.
Better Quality of Life
Patients treated with Advexin experienced far fewer harmful side effects such as pneumonia than those who received methotrexate. The incidence of inflammation of the mouth lining and a decrease in white blood cells, for example, both dropped to zero for those receiving Advexin.
"That certainly results in a better quality of life," Roth noted, which makes sense because p53 does not cause problems in normal cells.
Roth's lab has been developing gene therapy for cancer since 1990. "We wanted to go beyond conventional treatment, because most of those treatments were not very effective," Roth said. "Surgery and radiation are limited to the local tumor and once given, it's very hard to repeat those therapies. Chemotherapy inhibits DNA replication, but it also interferes with normal cells."
From idea to Phase I Trial at M. D. Anderson
All basic and preclinical work on the modified adenovirus was done at M. D. Anderson. The first phase I clinical trial was conducted by Gary Clayman, M.D., D.D.S., professor in M. D. Anderson's Department of head and neck surgery. Clayman also enrolled patients in the phase II and phase III clinical trials conducted by Introgen.
Roth and colleagues deleted an important region of the adenovirus' genome, preventing it from replicating. They installed a genomic segment that expresses p53. When injected into a tumor, the p53 adenovirus burrows into the cancer cell's nucleus. But instead of replicating in a typical viral manner, it expresses p53, resulting in cell death.
Clayman's phase I trial provided the first indicator that p53 expression in the tumor before treatment could be an accurate biomarker for p53 therapy. The concept was further developed retrospectively in Introgen's phase II trial, Roth said, and then it was applied prospectively in the phase III trial, with results related to biomarker status blinded until final data analysis.
If a tumor expresses high or low levels of normal p53, or a very low level of mutant p53, conditions are favorable for Advexin. Tumors with high levels of mutant p53 do not respond well to p53-related therapy. The healthy and mutant p53 biomarkers are easily discerned with standard lab techniques, Roth said immunohistochemical staining detects protein levels, while gene chip analysis reveals gene sequence.
Creation of Introgen
Roth found little interest in gene therapy from established pharmaceutical companies, so in 1994 he co-founded Introgen working through M. D. Anderson's Office of Technology Management.
Introgen has since grown into a publicly traded company on NASDAQ, and while it still licenses important technology from M. D. Anderson, the company works broadly with other medical research institutions and biotech firms.
Introgen developed a commercial-grade version of the drug and advanced it through phase II and III clinical trials for head and neck cancer. Advexin(r) also is being tested in other cancers in a variety of clinical trials.
"If something's going to get to patients, it has to be commercialized," Roth said. The National Cancer Institute funds basic and translational research but simply cannot afford to fund large, late-stage clinical trials, he said.
Nanotechnology and p53
Roth and colleagues now focus on ways to deliver p53 and other tumor-suppressing genes systemically - through intravenous delivery. Advexin has to be injected straight into the tumor, but that's not workable for many cancers. Head and neck cancer kills patients by recurring, not spreading to other organs, but most cancer deaths involve metastasis.
By wrapping tumor-suppressing genes in tiny balls of fat, Roth and colleagues hope to be able to treat more invasive cancers. While p53 nanoparticles are still in preclinical development, those that deliver another tumor-suppressor called FUS1 are in a phase I clinical trial for non-small cell lung cancer. Through 19 patients, the dose escalation study has yet to encounter significant side effects.
Injected nanoparticles gather mainly in tumors, where they are taken up and dissolved, leaving the tumor-suppressor gene at work in the cell. A version that combines FUS1 and p53 is under development.
University of Texas M. D. Anderson Cancer Center
The p53 gene is inactivated in many types of cancer. Its normal role is to halt the division of a defective cell and then force the cell to kill itself.
The trial showed that p53 expression in the patient's tumor before treatment is a reliable biomarker for how to treat head and neck cancer. Patients with a favorable p53 profile who received Advexin(r) had a median survival of 7.2 months, compared with 2.7 months for those whose tumor expressed high levels of mutant p53 before treatment. Patients with this unfavorable profile were better off taking the chemotherapy drug methotrexate, resulting in median survival of 5.9 months.
"The important finding is that patients who benefit from treatment can be identified with the p53 biomarker. The biomarker will enable physicians to personalize treatment," said Roth, who also directs M. D. Anderson's W.M. Keck Center for Innovative Cancer Therapies.
Detailed results of the 123-patient clinical trial, led by John Nemunaitis, M.D., executive director of the Mary Crowley Medical Research Center at Baylor-Charles A. Sammons Cancer Center in Dallas, are available at www.introgen.com.
Better Quality of Life
Patients treated with Advexin experienced far fewer harmful side effects such as pneumonia than those who received methotrexate. The incidence of inflammation of the mouth lining and a decrease in white blood cells, for example, both dropped to zero for those receiving Advexin.
"That certainly results in a better quality of life," Roth noted, which makes sense because p53 does not cause problems in normal cells.
Roth's lab has been developing gene therapy for cancer since 1990. "We wanted to go beyond conventional treatment, because most of those treatments were not very effective," Roth said. "Surgery and radiation are limited to the local tumor and once given, it's very hard to repeat those therapies. Chemotherapy inhibits DNA replication, but it also interferes with normal cells."
From idea to Phase I Trial at M. D. Anderson
All basic and preclinical work on the modified adenovirus was done at M. D. Anderson. The first phase I clinical trial was conducted by Gary Clayman, M.D., D.D.S., professor in M. D. Anderson's Department of head and neck surgery. Clayman also enrolled patients in the phase II and phase III clinical trials conducted by Introgen.
Roth and colleagues deleted an important region of the adenovirus' genome, preventing it from replicating. They installed a genomic segment that expresses p53. When injected into a tumor, the p53 adenovirus burrows into the cancer cell's nucleus. But instead of replicating in a typical viral manner, it expresses p53, resulting in cell death.
Clayman's phase I trial provided the first indicator that p53 expression in the tumor before treatment could be an accurate biomarker for p53 therapy. The concept was further developed retrospectively in Introgen's phase II trial, Roth said, and then it was applied prospectively in the phase III trial, with results related to biomarker status blinded until final data analysis.
If a tumor expresses high or low levels of normal p53, or a very low level of mutant p53, conditions are favorable for Advexin. Tumors with high levels of mutant p53 do not respond well to p53-related therapy. The healthy and mutant p53 biomarkers are easily discerned with standard lab techniques, Roth said immunohistochemical staining detects protein levels, while gene chip analysis reveals gene sequence.
Creation of Introgen
Roth found little interest in gene therapy from established pharmaceutical companies, so in 1994 he co-founded Introgen working through M. D. Anderson's Office of Technology Management.
Introgen has since grown into a publicly traded company on NASDAQ, and while it still licenses important technology from M. D. Anderson, the company works broadly with other medical research institutions and biotech firms.
Introgen developed a commercial-grade version of the drug and advanced it through phase II and III clinical trials for head and neck cancer. Advexin(r) also is being tested in other cancers in a variety of clinical trials.
"If something's going to get to patients, it has to be commercialized," Roth said. The National Cancer Institute funds basic and translational research but simply cannot afford to fund large, late-stage clinical trials, he said.
Nanotechnology and p53
Roth and colleagues now focus on ways to deliver p53 and other tumor-suppressing genes systemically - through intravenous delivery. Advexin has to be injected straight into the tumor, but that's not workable for many cancers. Head and neck cancer kills patients by recurring, not spreading to other organs, but most cancer deaths involve metastasis.
By wrapping tumor-suppressing genes in tiny balls of fat, Roth and colleagues hope to be able to treat more invasive cancers. While p53 nanoparticles are still in preclinical development, those that deliver another tumor-suppressor called FUS1 are in a phase I clinical trial for non-small cell lung cancer. Through 19 patients, the dose escalation study has yet to encounter significant side effects.
Injected nanoparticles gather mainly in tumors, where they are taken up and dissolved, leaving the tumor-suppressor gene at work in the cell. A version that combines FUS1 and p53 is under development.
University of Texas M. D. Anderson Cancer Center
Gene Therapy News and Current Gene Therapy Events RSSPrevious claims of siRNA therapeutic effects called into question by report in human gene therapy
The many recent reports documenting the therapeutic efficacy of short interfering RNAs (siRNAs) in animal models of human disease may actually be describing non-specific therapeutic effects related to the ability of siRNA to activate an immune response, according to a paper in the September 2008 issue (Volume 19, Number 9) of Human Gene Therapy, a peer-reviewed journal published by Mary Ann Liebert, Inc.
Study reveals how blood flow force prevents clogged arteries
Machines on cell surfaces, mechanical and lifeless as bed springs, protect blood vessels by responding to blood flow force, according to research published today in the Journal of Cell Biology.
UAB Anti-Cancer Research Featured in Scientific American
Scientific American magazine focused on two University of Alabama at Birmingham (UAB) Comprehensive Cancer Center researchers in a news story on experimental next-generation anti-cancer therapies.
Hydrogels provide scaffolding for growth of bone cells
Hyaluronic hydrogels developed by Carnegie Mellon University researchers may provide a suitable scaffolding to enable bone regeneration. The hydrogels, created by Newell Washburn, Krzysztof Matyjaszewski and Jeffrey Hollinger, have proven to encourage the growth of preosteoblast cells, cells that aid the growth and development of bone. Doctoral student Sidi Bencherif will present this research, Sunday, Aug. 17 at the 236th national meeting of the American Chemical Society in Philadelphia.
VCU Massey Cancer Center and VCU Institute of Molecular Medicine Researchers Publish Findings of a New Chemoprevention Gene Therapy That Kills Pancreatic Cancer Cells
Researchers at the Virginia Commonwealth University Massey Cancer Center and the VCU Institute of Molecular Medicine have published findings that implicate a new chemoprevention gene therapy (CGT) for preventing and treating pancreatic cancer, one of the most lethal and treatment-resistant forms of cancer.
Improved estrogen reception may sharpen fuzzy memory
Estrogen treatments may sharpen mental performance in women with certain medical conditions, but University of Florida researchers suggest that recharging a naturally occurring estrogen receptor in the brain may also clear cognitive cobwebs.
Consortium develops new method to manipulate genetic material
A multi-institutional team of researchers, including scientists at the University of Minnesota Medical School, have developed a powerful tool for genomic research and medicine.
NIST trumps the clumps: Making biologic drugs safer
Scientists at the National Institute of Standards and Technology (NIST) have developed a technique to measure the formation of clumps of proteins in protein-based pharmaceuticals.
Gene therapy research in developing world raises ethical red flags: experts
Early stage gene therapy clinical trials are recruiting patients from the developing world, providing medically deprived populations access to interventions that show promise but have largely unknown effects in humans.
New paradigm for cell-specific gene delivery
Researchers from Northwestern University and Texas A & M University have discovered a new way to limit gene transfer and expression to specific tissues in animals.
More Gene Therapy News Articles
 | Dr. Gundry's Diet Evolution: Turn Off the Genes That Are Killing You--And Your Waistline--And Drop the Weight for Good by Steven R. Dr Gundry YOUR GENES ARE TRYING TO KILL YOU– AND YOU’RE EATING IT UP!Does losing weight and staying healthy feel like a battle? Well, it’s really a war. Your enemies are your own genes, backed by millions of years of evolution, and the only way to win is to outsmart them.Dr. Steven Gundry explains what your body is “thinking” and tells you why, surprisingly, your genes... |
 | The Genie in Your Genes: Epigenetic Medicine and the New Biology of Intention by Dawson Church Author Dawson Church applies the insights of the new field of Epigenetics (epi=above, i.e. control above the level of the gene) to healing. Citing hundreds of scientific studies, he shows how beliefs and emotions can trigger the expression of DNA strands. He focuses on a class of genes called Immediate Early Genes or IEGs. These genes turn on within a few seconds of a stimulus. They can be... |
 | Narrative Therapy: The Social Construction of Preferred Realities by Jill Freedman, Gene Combs |
 | The Apo E Gene Diet: A Breakthrough in Changing Cholesterol, Weight, Heart and Alzheimer's Using the Body's Own Genes by Pamela Mcdonald Do you know your Apo E geneotype? Do you know why it's important? Researchers have discovered that the Apo E gene regulates the way your body transports fats and cholesterol, affecting not just weight but also the heart and vascular system, and influencing our patterns of inflammation--one of the key factors in many serious diseases. The Apo E Gene Diet is not a traditional diet; instead of... |
 | The Expressive Arts Activity Book: A Resource for Professionals by Suzanne Darley, Wende Heath |
 | The Gene Makeover: The 21st Century Anti-Aging Breakthrough by M.D. Giampapa Vincent C., M.D. Buechel, Sr. Frederick F., M.D. Karatoprak Ohan You know how victims and perpetrators are identified by their DNA on TV shows like "CSI" and "Law & Order." Now, that same science can help you lead a longer, healthier life. DNA-deoxyribonulceic acid-is the chemical inside your cells that carries the genetic instructions that make you unique. Aging occurs in DNA as cells replicate themselves continually in a process similar to photocopying. As... |
 | Whose Hands Are These?: A Gifted Healer's Miraculous True Story by Gene Egidio The book is the story of the life of the renowned healer, Gene Egidio. The story tells how he was reawakened to his powers by mere chance later in his life after his parents had forced Gene to forget his gift out of fear. It gives accounts of his ability to transform divine energy into practical... |
 | Gene Therapy (Special Topics in Biology Series) by Mary Colavito, Michael A. Palladino KEY MESSSAGE: Will gene therapy one day become the ultimate application of genetic technology? Gene Therapy, the newest booklet in the Special Topics in Biology Series, addresses this question by exploring gene therapy as a complex technology for delivering therapeutic genes as a way to treat and cure human genetic diseases. Author Mary Colavito provides an overview of the basic science involved... |
 | Genes, Environment, and Psychopathology: Understanding the Causes of Psychiatric and Substance Use Disorders by Kenneth S. Kendler, Carol A. Prescott This groundbreaking volume synthesizes the results of the Virginia Adult Twin Study of Psychiatric and Substance Use Disorders, which yielded longitudinal data on more than 9,000 individuals. The authors trace how risk for depression, anxiety, eating disorders, antisocial behavior, alcoholism, and substance abuse emerges from the interplay of a variety of genetic and environmental influences.... |
 | Gene Therapy: Treating Disease by Repairing Genes (New Biology) by Joseph, Ph.D. Panno |
| © 2008 BrightSurf.com |